Geneva, Switzerland (PRWEB) May 20, 2013
Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that the Company’s co-founder will present data on the Company’s core technology at the 2013 Cell Line Development & Engineering Conference, May 20 - 23 at the Hyatt Regency La Jolla at Aventine in La Jolla, California. Selexis’ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology and Faculty of Biology and Medicine at the University of Lausanne, will present, “Engineering the CHO Genome for Improved Transgene Integration and Expression,” on Monday, May 20 at 2:30 PM as part of the Application, Integration and Characterization of 'Omics in Cell Line Development tract.
Additionally, a poster presentation with data from the recently launched SURE CHO-Mplus™ Library, “CHO Cell Library for the Selection of Improved Recombinant Therapeutic Protein Production,” is scheduled to be presented at the conference. The poster presentation will discuss new solutions that address a broad range of recombinant protein secretion issues.
Epigenetic regulatory DNA elements prevent silencing and increase transgene integration and transcription for high and stable therapeutic production. We have sequenced the genome and transcriptome of a CHO cell line and of derived producer cell clones, yielding information on the integration locus, transgene integrity and copy number. Information on possible mechanisms allowing vector genomic integration was also obtained, providing approaches to further optimize transgene integration and expression.
In an effort to improve product yield of mammalian cell lines, we have previously demonstrated that our proprietary DNA elements, Selexis Genetic Elements (SGEs), increase the transcription of a given transgene, thus boosting the overall expression of a therapeutic protein drug in mammalian cells.
However, there are additional cellular bottlenecks, notably in the molecular machineries of the secretory pathways. Most importantly, mammalian cells have some limitations in their intrinsic capacity to manage high level of protein synthesis as well as folding recombinant proteins. These bottlenecks often lead to increased cellular stress and, therefore, low production rates.
Our specific approach involves CHO cell line engineering. We constructed a CHO-M library based upon the CHO-M genome and transcriptome and using unique proprietary transposon vectors harboring SGE DNA elements to compensate for rate-limiting factors. This CHO-Mplus library displays a diversity of greater than 1x107 auxiliary proteins involved in secretory pathway machineries and cellular metabolism.
We show that our CHO-Mplus library enabled the selection of a clonal cell line expressing 10 fold more product by comparison to standard approaches.
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:
# # #